Insulin analogs and insulin sensitizers are commonly used drugs for type 2 diabetes. Ace Therapeutics provides customized insulin analogs and insulin sensitizers discovery and preclinical assessment services to help our clients discover novel, safer antidiabetic drugs. Our comprehensive drug discovery solutions are designed to help clients improve insulin sensitivity and deliver more effective therapies.

Introduction of Insulin Analogs and Sensitizers

Insulin analogs include a range of substances that mimic the physiological function of insulin. They act by activating glucose transporter proteins on muscle and fat cells. Insulin sensitizers work by increasing the sensitivity of body tissues to insulin. In addition, insulin sensitizers can improve a variety of observable cardiac risk factors such as increased risk of blood clotting, elevated blood pressure, elevated lipid profile or C-reactive protein, adverse lipoproteins or serum fibrinogen, and even abnormal thickening of the myocardium.

Both types of drugs promote the uptake, utilization and storage of glucose by cells, thereby lowering blood sugar levels. However, there is an unmet need for safe and effective insulin analogs and insulin sensitizers. Therefore, the search for safer and novel drugs is necessary.

Fig. 1 Schematic representation of the mechanism of PPARγ agonist signaling. (Chen, Y.; et al., 2017)

Our Insulin Analog Development Services

Insulin analogs are a class of drugs that mimic the physiological function of insulin. Ace Therapeutics leverages our expertise to help our clients screen and identify insulin analogs candidates that can effectively bind to the insulin receptor, activate receptor signaling, and promote glucose uptake and utilization by cells.

• Screening of potential insulin analogs using in vitro models of pancreatic β-cells, L6 myotubes, 3T3-L1 adipocytes, and AML-12 hepatocytes.
• We fully assess the activity of insulin analogs by in vitro and in vivo assays, including insulin secretion, pancreatic β-cell viability, GSK3 β phosphorylation, lipolysis and glucose uptake.
• Comprehensive assessment of the efficacy and safety of insulin analogs candidates by in vivo models.

Our Insulin Sensitizer Development Services

The new generation of insulin sensitizers can be broadly classified into direct PPARγ agonists, selective PPARγ modulators (sPPARγ Ms) and PPARγ-sparing compounds (including ligands of the mitochondrial target of TZDs). Ace Therapeutics offers customized drug discovery strategies based on the mechanism of action of different insulin sensitizers. Whether you want to screen for promising insulin sensitizers, optimize a drug structure to improve selectivity and activity or assess a drug's efficacy and safety, we have a solution to match.

• We use in vitro cell systems such as adipocytes, muscle cells and hepatocytes to screen for potential insulin sensitizers and optimized their structure and activity based on the screening results.
• We use molecular biology techniques and in vitro models to assess the effects of drugs on insulin signaling pathways and insulin secretion.
• We measure plasma insulin, FFA, food consumption and body weight of test animals in in vivo assays to provide a comprehensive assessment of the efficacy of insulin sensitizers candidates.
• Our comprehensive pharmacokinetic analyses and drug safety studies are performed to ensure that novel insulin sensitizers are screened with high efficacy and low side effects for our clients.

Our One-Stop Solutions for Insulin Analog and Sensitizer Development

Ace Therapeutics is committed to providing professional, efficient insulin analogs and sensitizers development solutions to help clients accelerate their antidiabetic drug development process. Please contact us for more details and we will provide you with customized strategies.

References

1. Chen, Y.; et al. Discovery of novel insulin sensitizers: promising approaches and targets. PPAR research. 2017, 2017(1): 8360919.
2. Rozenberg, K.; et al. Insulin-sensitizing and insulin-mimetic activities of Sarcopoterium spinosum extract. Journal of ethnopharmacology. 2014, 155(1): 362-372.
3. Kanwal, A.; et al. Exploring new drug targets for type 2 diabetes: success, challenges and opportunities. Biomedicines. 2022, 10(2): 331.

• Insulin Secretagogue Development Services
• Starch Blocker Development Services

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators